Profile data is unavailable for this security.
About the company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
- Revenue in USD (TTM)23.09bn
- Net income in USD5.53bn
- Incorporated1901
- Employees33.63k
- LocationEli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
- Phone+1 (317) 276-2000
- Fax+1 (317) 276-3492
- Websitehttps://www.lilly.com/
Mergers & acquisitions
| Acquired company | LLY:NYQ since announced | Transaction value |
|---|---|---|
| Dermira Inc | 20.33% | 1.07bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 22.72bn | 4.96bn | 95.73bn | 11.80k | 19.62 | 4.34 | 15.13 | 4.21 | 3.89 | 3.89 | 17.86 | 17.60 | 0.3706 | 4.98 | 6.32 | 1,925,085.00 | 8.05 | 18.07 | 9.48 | 21.88 | 79.37 | 83.42 | 21.72 | 39.31 | 2.92 | 21.20 | 0.5207 | 25.34 | 1.46 | -2.04 | -1.34 | -14.95 | 8.17 | -- |
| Bristol-Myers Squibb Co | 31.01bn | 954.00m | 129.95bn | 30.00k | 70.99 | 2.60 | 25.59 | 4.19 | 0.809 | 0.809 | 16.65 | 22.06 | 0.3779 | 4.64 | 5.26 | 1,033,533.00 | 1.19 | 8.56 | 1.44 | 11.21 | 69.16 | 72.59 | 3.16 | 17.51 | 1.51 | 5.32 | 0.4831 | 72.45 | 15.89 | 10.49 | -30.89 | 11.41 | 9.71 | 2.64 |
| Amgen, Inc. | 23.97bn | 7.68bn | 146.50bn | 23.40k | 19.51 | 15.44 | 14.25 | 6.11 | 12.77 | 12.77 | 39.89 | 16.13 | 0.3814 | 1.44 | 5.46 | 1,024,188.00 | 12.21 | 10.83 | 15.18 | 12.67 | 79.91 | 81.75 | 32.02 | 34.01 | 1.28 | 13.40 | 0.7705 | 41.54 | -1.62 | 3.09 | -6.58 | 8.74 | -9.23 | 18.91 |
| Eli Lilly And Co | 23.09bn | 5.53bn | 156.25bn | 33.63k | 27.08 | 50.75 | 23.38 | 6.77 | 6.03 | 6.03 | 25.16 | 3.22 | 0.5837 | 1.56 | 4.49 | 686,605.20 | 13.99 | 8.76 | 20.10 | 12.28 | 79.22 | 76.62 | 23.97 | 16.77 | 0.8637 | 2.76 | 0.8435 | 64.42 | 3.84 | 2.62 | 39.45 | 14.17 | -2.87 | 5.65 |
| AbbVie Inc | 34.06bn | 8.39bn | 170.65bn | 30.00k | 17.13 | -- | 16.24 | 5.01 | 5.65 | 5.65 | 22.94 | -5.02 | 0.4603 | 4.41 | 5.66 | 1,135,233.00 | 11.40 | 9.90 | 14.35 | 12.72 | 77.06 | 77.14 | 24.77 | 21.34 | 3.03 | 9.09 | 1.12 | 79.29 | 1.57 | 10.76 | 36.55 | 34.62 | -2.04 | 20.86 |
| Pfizer Inc. | 50.66bn | 15.47bn | 187.92bn | 88.30k | 12.36 | 2.89 | 8.87 | 3.71 | 2.74 | 2.80 | 8.99 | 11.71 | 0.3149 | 1.21 | 5.20 | 573,725.90 | 9.63 | 6.27 | 12.02 | 7.68 | 80.37 | 79.40 | 30.59 | 20.23 | 0.7765 | -- | 0.4445 | 73.76 | -3.54 | 0.8503 | 54.15 | 11.91 | 10.38 | 6.72 |
| Merck & Co., Inc. | 48.08bn | 10.20bn | 193.67bn | 71.00k | 19.30 | 7.39 | 14.08 | 4.03 | 3.97 | 3.96 | 18.73 | 10.38 | 0.5749 | 2.32 | 6.09 | 677,211.30 | 12.18 | 6.50 | 16.29 | 8.27 | 72.17 | 67.93 | 21.18 | 14.30 | 0.8657 | 28.97 | 0.5156 | 88.98 | 10.75 | 2.09 | 53.02 | -3.53 | 21.40 | 5.13 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2020 | 68.46m | 7.15% |
| BlackRock Fund Advisorsas of 31 Mar 2020 | 44.51m | 4.65% |
| PRIMECAP Management Co.as of 31 Mar 2020 | 41.94m | 4.38% |
| SSgA Funds Management, Inc.as of 31 Mar 2020 | 37.05m | 3.87% |
| Wellington Management Co. LLPas of 31 Mar 2020 | 36.02m | 3.76% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2020 | 26.50m | 2.77% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2020 | 22.78m | 2.38% |
| State Farm Investment Management Corp.as of 31 Mar 2020 | 18.62m | 1.95% |
| Geode Capital Management LLCas of 31 Mar 2020 | 12.65m | 1.32% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2020 | 10.92m | 1.14% |
